BridgeBio Oncology Therapeutics, Inc. (BBOT) — Financial Flexibility Index
BridgeBio Oncology Therapeutics, Inc. (BBOT) has a Financial Flexibility Index of -0.79x as of March 2026. Free cash flow of $-35.89 Million (operating CF $-35.92 Million minus capex $24.00K) represents -1% of total liabilities ($45.37 Million). Check BBOT intangible-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
BridgeBio Oncology Therapeutics, Inc. Financial Flexibility Index (2023–2025)
Historical Financial Flexibility Index trend for BridgeBio Oncology Therapeutics, Inc. across 3 annual periods. For the full cash flow conversion analysis, see cash flow conversion of BridgeBio Oncology Therapeutics, Inc..
Annual Financial Flexibility Index for BridgeBio Oncology Therapeutics, Inc. (2023–2025)
Year-by-year free cash flow to debt coverage for BridgeBio Oncology Therapeutics, Inc.. Explore cash flow to debt ratio of BridgeBio Oncology Therapeutics, Inc. to assess how comfortably operating cash covers total debt obligations.
| Year | Flexibility Index | Free Cash Flow (USD) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | -3.04x | $-113.29 Million | $-113.89 Million | $37.28 Million | ▼ -2326.1% |
| 2024 | -0.13x | $-714.82K | $-763.82K | $5.71 Million | ▲ +99.9% |
| 2023 | -130.31x | $-51.66 Million | $-52.08 Million | $396.46K | — |